The quality agreement outlining the responsibilities for fabricating, packaging or labelling, and/or testing was inadequate.
Inspection Record
Leda Health Innovations Inc. — Health Canada Inspection Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
The implementation of a self-inspection program was inadequate.
The written specifications were inadequate.
The ongoing stability program for a drug was inadequate.
The ongoing training of personnel was inadequate.
Investigations into deviations, reports, and/or follow-up actions were inadequate.
The maintenance of evidence was inadequate for manufacturing, packaging, labelling, required testing, storage, and/or distribution, including the respective conditions.
About this record
Extracted automatically from the document of the Health Canada inspection on 2023-01-17. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
